2018 American Society of Clinical Oncology (ASCO) Annual Meeting - X4 Pharmaceuticals

2018 American Society of Clinical Oncology (ASCO) Annual Meeting

2018 American Society of Clinical Oncology (ASCO) Annual Meeting

June 2018

A Phase 1/2 Study Evaluating the Efficacy and Safety of the Oral CXCR4 Inhibitor X4P-001 in Combination with Axitinib in Patients with Advanced Renal Cell Carcinoma

© 2023 X4 Pharmaceuticals, Inc. All rights reserved. Terms of Use | Privacy Policy